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ABSTRACT
We  report  a  74  year  old  lady  presenting  with  cutaneous 
leukocytoclastic  vasculitis.  The  underlying  aetiology  was 
established as chronic hepatitis C infection with associated 
cryoglobulinaemia.  This  presented  clinically  as  recurrent 
cutaneous  vasculitic  eruptions  with  absence  of  any  other 
clinical manifestations. In this case, antiviral treatment to 
eradicate hepatitis C virus (HCV) was deemed inappropriate 
given  the  low  necroinflammatory  score  determined 
by  liver  biopsy,  absence  of  other  systemic  sequelae  of 
cryoglobulinaemia  and  potential  risks  of  therapy  given 
her age.  Currently her cutaneous disease is relatively well 
controlled  with  intermittent  application  of  potent  topical 
steroids.  This case highlights the need to consider hepatitis C 
as a potential aetiological factor in all patients with cutaneous 
vasculitis. We suggest that viral hepatitis screening should be 
routine in all patients presenting with cutaneous vasculitis.
INTRODUCTION
Cutaneous  vasculitis  is  a  common  diagnosis  encountered 
in  routine  dermatology  practice.  Underlying  autoimmune 
diseases, malignancy, drugs and systemic vasculitis are often 
found to be aetiological factors. Infections also play a major 
role including streptococcus, staphylococcus, mycobacterium 
and hepatitis B or C1,2. We present a case of occult chronic 
hepatitis C with associated cryoglobulinaemia manifesting as 
a cutaneous leukocytoclastic vasculitis in an elderly lady.
CASE REPORT  
A 74 year old lady presented to dermatology out-patients with 
an eight year history of a recurrent tender, non-blanching, 
palpable, purpuric rash involving her lower limbs (figs 1 and 
2).  A diagnostic punch biopsy revealed a leukocytoclastic 
vasculitis. She had no significant medical history and denied 
systemic upset, recent infections or new medications.
Laboratory  investigations  confirmed  normal  full  blood 
count, renal, liver and thyroid function with an absence of 
microscopic  haematuria  and  red  cell  casts  on  urinalysis 
testing. Inflammatory markers, autoimmune screen, double 
stranded DNA, pANCA and cANCA were all negative and 
remained so on repeated sampling. Normal anti-streptolysin O 
Fig 1. Lower limbs showing vasculitis
Fig 2. Close up view showing vasculitis© The Ulster Medical Society, 2008.
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titre, complement and immunoglobulin levels were reported. 
Chest  radiograph  was  normal.  Rheumatoid  factor  was 
positive. Chronic hepatitis C virus infection was confirmed by 
enzyme immunoassay and reverse-transcriptase polymerase 
chain reaction. The virus was typed by limited sequencing of 
the 5′ non-coding region of the virus and was confirmed as 
genotype 2. The HCV specific antibody level was abnormally 
low, in keeping with immune-complex sequestration.
Given  the  association  between  hepatitis  C  infection  and 
type II [mixed] cryoglobulinaemia, the presence of serum 
cryoglobulins  was  sought  and  detected.  A  diagnosis  of 
hepatitis C related cryoglobulinaemic cutaneous vasculitis 
was made. Her only risk factor for contraction of hepatitis C 
was a blood transfusion received in 1954 in the United States 
following a spontaneous abortion.
She was referred to the regional hepatology unit for further 
assessment including consideration of hepatitis C eradication 
therapy. Subsequent liver biopsy revealed changes consistent 
with chronic hepatitis C infection with a necroinflammatory 
score of only 1 out of a possible 8 and a modified staging 
score of 0. Eradication of hepatitis C virus with interferon 2 
alpha plus ribavirin was deemed inappropriate in this patient 
given the low necroinflammatory score on liver biopsy, the 
absence of other systemic sequelae of cryoglobulinaemia and 
potential risks of therapy. Intermittent use of potent topical 
steroids has to date controlled exacerbations of her cutaneous 
vasculitis and prevented progression to ulceration.
DISCUSSION
At the time of initial presentation to dermatology out-patients 
there was no reason to have a clinical suspicion of chronic 
hepatitis C infection in this otherwise healthy elderly woman. 
A study of hepatitis C in Northern Ireland by McDougall3 
described  78%  of  patients  as  asymptomatic  at  the  time 
of  diagnosis  -  a  figure  substantiated  by  earlier  studies3,4. 
An  increased  awareness  of  HCV  infections’  cutaneous 
manifestations may enhance its chances of detection. 
Our patient presented with palpable purpura but this is just 
one  such  cutaneous  indication  of  underlying  hepatitis  C 
infection. Others include livedo reticularis, urticaria, lichen 
planus,  erythema  multiforme,  erythema  nodosum  and 
porphyria cutanea tarda5-8.
Subsequent  detection  of  cryoglobulins  in  our  patient 
confirmed  the  underlying  pathology  responsible  for  the 
leukocyclastic vasculitis.  Cryoglobulins are immunoglobulins 
that precipitate at temperatures below 370C and re-dissolve 
with  warming.  Cryoglobulinaemia  can  manifest  in  two 
ways.    Firstly,  by  precipitation  and  obstruction  of  small 
blood vessels in the peripheries [feet, hands, nose and ears] 
resulting  in  cutaneous  ischaemia  and  possible  infarction. 
Secondly,  by  deposition  as  immune  complexes  thereby 
initiating  a  leukocytoclastic  vasculitis.  Depending  on  the 
site  of  deposition,  various  clinical  entities  may  arise  – 
palpable purpura, arthritis, glomerulonephritis or peripheral 
neuropathy. Our patients’ vasculitis was limited to cutaneous 
involvement.
Cryoglobulinaemia  is  classified  into  three  types.  Type  I 
consists of a single monoclonal immunoglobulin [Ig], usually 
a  paraprotein,  which  is  associated  with  haematological 
disorders.  Type  II  is  characterised  by  polyclonal  IgG 
rheumatoid factor and monoclonal IgM rheumatoid factor. 
Polyclonal IgG and IgM rheumatoid factors are found in type 
III.  Types II and III are known as mixed cryoglobulinaemia 
and can be associated with several conditions. Haematological 
associations include lymphoma and myeloma. It also exists 
with  autoimmune  disorders  such  as  rheumatoid  arthritis 
and systemic lupus. Infections implicated include parasitic, 
bacterial and viral infections, of which HCV is more common 
than hepatitis B virus.
Essential  mixed  cryoglobulinaemia  is  a  term  used  to 
describe  mixed  cryoglobulinaemia  occurring  without 
identification of a primary disease. Evidence suggests that 
HCV infection may well be responsible for a majority of 
those cases previously defined as ‘essential’9.  Anti-HCV 
antibodies  are  found  in  70-100%  of  patients  with  mixed 
cryoglobulinaemia10.  Contrastingly,  among  patients  with 
chronic HCV infection, one third to one half have serological 
markers of cryoglobulinaemia but the clinical syndrome of 
mixed cryoglobulinaemia, as manifested in this case, occurs 
rarely in only 1-2%11,12.
The  definitive  management  of  hepatitis  C  related 
cryoglobulinaemia  is  by  eradication  of  the  virus  with 
subsequent suppression of the cryoglobulinaemic process. 
Use of pegylated interferon alpha [IFN-alpha] 2a or 2b in 
combination with ribavirin has been shown to be effective 
with sustained virological response [defined as undetectable 
viraemia 24 weeks after the end of therapy] reported as 76% 
using 24 weeks of IFN-alpha 2a plus ribavirin and 82% using 
IFN-alpha 2b plus ribavirin for the genotype group applicable 
to our patient - genotype 2 or 313,14. 
The  decision  not  to  offer  IFN-alpha  combined  with   
ribavirin  therapy  to  this  patient  was  based  on  her  age, 
low  necroinflammatory  score  on  liver  pathology  and  risk 
of    significant  side  effects  such  as  myelosuppression, 
polyarthritis, thyroiditis and peripheral neuropathy. Alternative 
therapies which have been implemented for cutaneous mixed 
cryoglobulinaemia are systemic prednisolone, azathioprine, 
mycophenolate, dapsone or plasmapheresis. More recently, 
rituximab has been used successfully15.
Currently,  this  lady’s  flares  of  cutaneous  vasculitis  are 
successfully treated to resolution with topical agents only. 
If, however, the cutaneous features become unresponsive to 
topical measures or further sequelae of cryoglobulinaemia 
should  develop,  further  consideration  will  be  given  to 
treatment with pegylated IFN-alpha combined with ribavirin 
or alternatively a systemic immunosuppressant agent. 
In  summary,  our  case  report  highlights  the  interesting 
association  between  hepatitis  C  virus,  cryoglobulinaemia 
and leukocytoclastic vasculitis. Heightened awareness of all 
the cutaneous manifestations of hepatitis C can only serve 
to  increase  the  diagnostic  rate  of  a  notoriously  clinically 
silent infection. Although cutaneous vasculitis is a relatively 
common clinical presentation, this case emphasises the need 
to perform full screening investigations to exclude the least 
prevalent aetiologies and to consider underlying hepatitis C 
infection, even in those you least suspect. 
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